Skip to main
AGLE
AGLE logo

Aeglea BioTherapeutics (AGLE) Stock Forecast & Price Target

Aeglea BioTherapeutics (AGLE) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%
Aeglea BioTherapeutics (AGLE) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aeglea BioTherapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aeglea BioTherapeutics (AGLE) Forecast

Analysts have given Aeglea BioTherapeutics (AGLE) a Buy based on their latest research and market trends.

According to 8 analysts, Aeglea BioTherapeutics (AGLE) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aeglea BioTherapeutics (AGLE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.